BioLineRx (NASDAQ:BLRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report report published on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright lowered their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

BioLineRx Stock Up 7.1 %

BLRX stock opened at $0.27 on Friday. The stock has a market capitalization of $21.89 million, a P/E ratio of -1.24 and a beta of 1.39. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. BioLineRx has a 1-year low of $0.19 and a 1-year high of $1.58. The business has a fifty day moving average price of $0.32 and a 200-day moving average price of $0.52.

Hedge Funds Weigh In On BioLineRx

Several hedge funds and other institutional investors have recently modified their holdings of BLRX. Atria Investments Inc lifted its holdings in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the period. PVG Asset Management Corp purchased a new stake in shares of BioLineRx during the 2nd quarter valued at about $70,000. Finally, CVI Holdings LLC bought a new position in shares of BioLineRx in the 2nd quarter worth approximately $462,000. 1.56% of the stock is owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.